Latest news

• Moderna says its COVID-19 vaccine appears effective against Delta and other variants

  However, Moderna noted that there was a six-fold reduction in neutralising antibodies observed with the B.1.351 strain, although the company added that the levels induced by its vaccine ... The data includes information on two candidates – mRNA-1273.351

• Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study

  Study will investigate two formulations targeting the Wuhan strain and the South African variant. ... another formulation targeting the South African or B.1.351 variant.

• Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

  The submission includes data from Pfizer’s clinical programme evaluating 20vPnC in adults, including phase 1 and 2 trials and three phase 3 trials describing the safety and evaluating the immunogenicity ... The companies also announced that they are

• Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants

  The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant B.1.351. ... In addition, the new results found that a booster dose of mRNA-1273.351 achieved higher neutralising antibody titres against

• CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

  CureVac is also working towards addressing variants of concerns, namely the B.1.351 variant first identified in South Africa. ... 1.351 variant.